Clinical trials in Castelfranco Veneto

36 clinical trials in Castelfranco Veneto, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Castelfranco Veneto at a glance

clinical trials

Paediatric trials0
Research sites0

Quick filters

36 trials in Castelfranco Veneto

Open in trial search

Bladder transitional cell carcinoma

Recruiting

Study of nadofaragene firadenovec alone or with gemcitabine, docetaxel or pembrolizumab in adults with non-muscle invasive bladder cancer who did not respond to BCG therapy

Registered drugNo placebo

Study of nadofaragene firadenovec alone or with gemcitabine, docetaxel or pembrolizumab in adults with non-muscle invasive bladder cancer who did not respond to BCG therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Ferring Pharmaceuticals A/S

Contact Research Centre

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Ruxolitinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Hormone-refractory prostate cancer+1

Recruiting

A study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

A study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Acute myeloid leukaemia

Recruiting

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Bleximenib
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

Investigational

A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:JNJ-78278343
Sponsor:Janssen Cilag International

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of gilteritinib with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed FLT3-positive acute myeloid leukemia patients

Registered drugNo placebo

Study of gilteritinib with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed FLT3-positive acute myeloid leukemia patients

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Gilteritinib
Sponsor:Fondazione Gimema Franco Mandelli Onlus

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

Registered drugNo placebo

Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Busulfan
Sponsor:Fondazione Gimema Franco Mandelli Onlus

Contact Research Centre

Peripheral arterial occlusive disease+1

Recruiting

Study on Low-Dose Colchicine for Patients with Peripheral Artery Disease to Reduce Cardiovascular Risks

Registered drug

Study on Low-Dose Colchicine for Patients with Peripheral Artery Disease to Reduce Cardiovascular Risks

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Colchicine
Sponsor:Hamilton Health Sciences Corporation

Contact Research Centre

Ovarian cancer stage IV+1

Recruiting

Study on Letrozole vs. Chemotherapy (Carboplatin and Paclitaxel) for Patients with Advanced Low-Grade Serous Ovarian Cancer with Hormone Receptors

Registered drugNo placebo

Study on Letrozole vs. Chemotherapy (Carboplatin and Paclitaxel) for Patients with Advanced Low-Grade Serous Ovarian Cancer with Hormone Receptors

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Ente Ospedaliero Ospedali Galliera Di Genova

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study on the Effectiveness of Gilteritinib and Drug Combination for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo

Study on the Effectiveness of Gilteritinib and Drug Combination for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Amsacrine
Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Contact Research Centre

Chronic lymphocytic leukaemia

Recruiting

Study of Ibrutinib for Treating Autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia or Similar Conditions

Registered drugNo placebo

Study of Ibrutinib for Treating Autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia or Similar Conditions

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:Fondazione Gimema Franco Mandelli Onlus

Contact Research Centre

Myelodysplastic syndrome

Recruiting

Study of Azacitidine and Drug Combination Before Stem Cell Transplantation in Patients with High-Risk Myelodysplastic Syndrome

Registered drugNo placebo

Study of Azacitidine and Drug Combination Before Stem Cell Transplantation in Patients with High-Risk Myelodysplastic Syndrome

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Fondazione Gimema Franco Mandelli Onlus

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Castelfranco Veneto

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on blood-related cancers, including studies of Acute Myeloid Leukemia, Follicular Lymphoma, and Chronic Myeloid Leukemia. Clinical trials are evaluating innovative combination therapies and maintenance treatments.

Leukemia Treatment Optimization
Lymphoma Management
Novel Drug Combinations

Multiple trials are investigating immunotherapy approaches and targeted treatments to improve patient outcomes.

02 Cardiovascular Medicine

Studies addressing peripheral arterial disease and vascular complications. Research includes innovative approaches using established medications for new cardiovascular applications.

Vascular Risk Management
Thrombosis Prevention
Cardiovascular Outcomes

Trials focus on reducing major cardiovascular events and improving long-term patient outcomes.

03 Solid Tumor Oncology

Research initiatives targeting various solid tumors, including bladder cancer and biliary tract cancers. Studies are evaluating combination approaches with immunotherapy and conventional treatments.

Immunotherapy Applications
Treatment Resistance
Novel Drug Development

Emphasis on developing more effective and less toxic treatment options for cancer patients.

Back to Italy All countries